TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00940368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provision of capsules containing ginger powder or placebo
Description: The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Provision of capsules containing ginger powder or placebo
Description: The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.
Study: NCT03858257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard oxygenation
Description: Supplemental oxygen through a facemask.
Study: NCT01989091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Lock
Description: Antimicrobial Catheter Lock Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 5,000 U/mL
Description: Standard of Care Catheter Lock Solution
Study: NCT03180866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luma Light System
Description: The Luma Light System combines a NBUVB light with an occlusive dressing.
Study: NCT04051242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XenMatrix™ AB Surgical Graft
Description: Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
Study: NCT02141256

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enriched products
Description: Newly developed products with extra protein. Specially developed for elderly.
Study: NCT02716025

Intervention type: PROCEDURE
Intervention: Upper gastrointestinal endoscopy
Description: Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
Study: NCT03254251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair climbing
Description: Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
Study: NCT03820713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrate of plasma coagulation factors
Description: The plasma concentrate of coagulation factors is applied to the surgical site.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
Study: NCT02878109

Intervention type: DEVICE
Intervention: Post-treatment phase group
Description: 4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)

Intervention type: DEVICE
Intervention: Pre-treatment phase group
Description: 4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
Study: NCT03783208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
Study: NCT02530762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided in one serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided in one serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Fiber
Description: novel fiber supplemented beverage provided in one serving

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Fiber control
Description: positive control fiber supplemented beverage provided in one serving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: No added fiber beverage
Study: NCT01023074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auditory training
Description: the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MS: Control Activity
Description: MS group not receiving auditory training, doing control activity
Study: NCT01714570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: 4.5g q6h, 5-10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: 0.5g q6h, 5-10 days
Study: NCT04355455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 40 mg citalopram intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT01188837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full Kinetic Chain Manipulative Therapy
Description: Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full Kinetic Chain Rehabilitation
Description: Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full Kinetic Chain Manipulative Therapy with Rehabilitation
Description: This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
Study: NCT01856153

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Before meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: With Meal

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: After meal
Study: NCT00944697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Naloxone
Description: Oxycodone Naloxone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo Oxycodone Naloxone tablets
Study: NCT04682002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Administration of routine care based on international guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical nutrition
Description: Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: There will be five personalized coaching sessions during the pregnancy.
Study: NCT02896361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol
Description: Stimulation parameters are reprogrammed from original values to study defined ones

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol
Description: Stimulation parameters are reprogrammed from original values to study defined ones

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol
Description: Stimulation parameters are reprogrammed from original values to study defined ones
Study: NCT04450745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia
Description: 60 minutes training program of mixed exercise in normobaric hypoxic chamber

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise in normoxia
Description: 60 minutes training program of mixed exercise in regular air conditions
Study: NCT03601663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Information
Description: Participants will receive a copy of the Canadian Physical Activity Guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Information
Description: Participants will receive a copy of the Canadian Physical Activity Guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Information
Description: Participants will receive a copy of the Canadian Physical Activity Guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring
Description: Participants will receive a wearable activity tracker (Polar A300).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring
Description: Participants will receive a wearable activity tracker (Polar A300).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy-support
Description: Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
Study: NCT01252069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, placebo, drug free period
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, progestin, drug free period
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
Study: NCT02688556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of OTX-101
Study: NCT01287013

Intervention type: DEVICE
Group type: OTHER
Intervention: Cone-beam computed tomography (CT)
Description: Imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Computed Tomography (CT)
Description: Imaging
Study: NCT04496635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a bundle of care
Study: NCT01373970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole + Placebo
Description: Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
Study: NCT02256085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily rTMS with Active coil
Description: rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Daily rTMS with Sham coil
Description: rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Label Daily rTMS with Active coil
Description: rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
Study: NCT01210456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
Description: All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
Description: All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.
Study: NCT02925442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: t-RFA
Description: standard thermal genicular radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: C-RFA
Description: Cooled radiofrequency ablation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Simulated radiofrequency ablation for placebo controlled group
Study: NCT02363790

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LVHR PFC
Description: Information included in arm description

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bridging LVHR
Description: Information included in arm description
Study: NCT00620009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy Feedback
Description: Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
Study: NCT00146523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03732846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
Study: NCT03996512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Active Controlled Motion (EACM)
Description: Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
Study: NCT01118936

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium supplement (magnesium hydroxide/ -oxide)
Description: 3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets of placebo daily for 12 weeks
Study: NCT03702621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal Bupivacaine
Description: 20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group
Study: NCT01574248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icatibant
Description: Subcutaneous at time 0 and 6 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous at time 0 and 6 hours
Study: NCT01469546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST \[Response Evaluation Criteria In Solid Tumors\] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
Study: NCT01575522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT01491581

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: food bar
Description: milk based food bar enriched with micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food bar
Description: milk based food bar enriched with micronutrients
Study: NCT02962128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid (LA) Diet
Description: Volunteers will be randomly assigned to consumption of a high \[10% energy\] LA-containing diet for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Linoleic Acid (LA) Diet
Description: Volunteers will be randomly assigned to consumption of a low \[2.5% energy\] LA-containing diet for 12 weeks.
Study: NCT03034083

Intervention type: BEHAVIORAL
Intervention: Elevate
Description: Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
Study: NCT01195259

Intervention type: DRUG
Intervention: allocation of treatment with metformin or rosiglitazone
Description: Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.

Intervention type: DRUG
Intervention: allocation of treatment with metformin or rosiglitazone
Description: Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
Study: NCT01649622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.